Global Coverage

With 87 years of experience, Atabay is one of Türkiye’s leading manufacturers of finished pharmaceutical products and Active Pharmaceutical Ingredients (APIs), exporting to 67 countries across five continents.

Supported by internationally compliant manufacturing infrastructure, strong regulatory expertise, and an extensive global network, Atabay is positioned as a reliable and sustainable business partner worldwide.

Global Presence and Strategic Structure

Atabay supports its international growth not only through a distributor model but also through direct local operations.

Operating across five continents through 41 distributors, the company:

• Manages direct sales and public tenders in Kazakhstan through its own office and local team,
• Conducts marketing and business development activities via its representative office in Bulgaria,
• Strengthens its position in Vietnam through locally registered products and commercial operations,
• Plans to reinforce its European presence with a representative office in the United Kingdom.

As of 2025, export volume has exceeded USD 20 million (approximately TRY 840 million), reflecting Atabay’s quality-driven manufacturing approach and sustainable growth strategy.

API Manufacturing Strength

In addition to finished pharmaceutical products, Atabay exports Active Pharmaceutical Ingredients (APIs) for human, veterinary, and agricultural use to numerous countries worldwide.

Manufacturing operations are carried out at the integrated facilities in Gebze, Kocaeli, in accordance with:

• EU GMP (Good Manufacturing Practices) standards,
• FDA compliance requirements,
• Internationally recognized pharmaceutical quality systems.

As one of Türkiye’s largest domestic manufacturers of Paracetamol API, Atabay holds a strategic position in the global supply chain with its strong production capacity and integrated manufacturing structure.

Amitraz API, developed for veterinary and agricultural applications, is produced in modern facilities and supplied reliably to international markets.

New Markets and Growth Outlook

In 2025, Atabay secured 31 new product registrations across 8 countries.
Target markets for 2026 include Canada, Qatar, Kuwait, the Philippines, Bulgaria, and Mongolia.

Atabay continues to strengthen its global presence through a sustainable and balanced growth strategy.

Global Responsibility

Beyond commercial success, Atabay prioritizes social responsibility. As an approved pharmaceutical supplier of UNICEF in Türkiye, the company contributes to improving children’s health worldwide, reflecting its ethical values and people-centered approach.